Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
|
22898488 |
2012 |
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Steatotic HCC did not differ from HCC without significant steatosis in immunohistochemical expression of FABP1 and SHH and PNPLA3 gene polymorphism.
|
27380543 |
2016 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Because PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants are known to confer susceptibility to NAFLD, we assessed the influence of MBOAT7 rs641738 on hepatic steatosis, and serum levels of CK-18 fragment (a biomarker of hepatocellular injury and apoptosis for NAFLD) after adjusting the effects of PNPLA3, GCKR and TM6SF2 polymorphisms.
|
29314568 |
2018 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
PNPLA3 carriers showed higher steatosis, portal inflammation and HpSC niche activation compared to wild-type patients.
|
29150621 |
2017 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A recent finding that a nonsynonymous polymorphism in the PNPLA3 gene predicts the extent of steatosis in NAFLD has been replicated in at least eight studies, with several studies also demonstrating an association with fibrosis.
|
21476920 |
2011 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Using a 443 patient training set, protein biomarker discovery was performed using the highly multiplexed SOMAscan<sup>®</sup> proteomic assay, a set of 19 clinical variables, and the steatosis predisposing PNPLA3 rs738409 single nucleotide polymorphism genotype status.
|
28266614 |
2017 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A recent genome-wide association study identified genetic polymorphism (rs738409 C>G) in the PNPLA3/adiponutrin gene associated with liver steatosis.
|
21334404 |
2011 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Since DAG (FA18:1) has been implicated in hepatic insulin resistance, the unaltered proportion of DAG (FA18:1) in I148M PNPLA3 carriers with fatty liver may explain the normal insulin sensitivity in these subjects.
|
30227635 |
2018 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Although African Americans are less susceptible to fatty liver than European Americans, PNPLA3 appears to be a risk locus for hepatic steatosis in diabetic African Americans.
|
21665509 |
2011 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
IL28B and PNPLA3 are associated with hepatic steatosis prevalence and severity in Caucasians with G1 HCV, suggesting differing potential genetic risk pathways to steatosis.
|
22543885 |
2012 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of the minor PNPLA3 p.I148M risk allele increased the risk of developing NAFLD (OR = 3.29, P < 0.001) and was associated with higher steatosis, fibrosis, and serum CK18-M30 levels (all P < 0.05).
|
29483677 |
2018 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
This study aimed to confirm the association of the transmembrane 6 superfamily member 2 (TM6SF2) E167K variant with non-alcoholic fatty liver disease (NAFLD) and the degree of steatosis, as well as the additive effect of body mass index (BMI) or the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M and TM6SF2 E167K variants in NAFLD.
|
31054977 |
2020 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
|
26745555 |
2016 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In multivariable analysis, HIV infection was associated with a lower prevalence of fatty liver (odds ratio (OR)=0.44, P=0.002), whereas a higher prevalence of fatty liver was seen in participants with PNPLA3 (rs738409) non-CC genotype (OR=2.06, P=0.005), more abdominal visceral adipose tissue (OR=1.08 per 10 cm(2), P<0.001), and homeostatic model assessment of insulin resistance (HOMA-IR) ≥4.9 (OR=2.50, P=0.001).
|
24642579 |
2014 |
Steatohepatitis
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The up-regulation of expression of hepatic genes related to liver steatosis (CPT1A, FASN, LEPR, RXRA, IGFBP1, PPARGC1A and SLC2A4) was detected in our rhesus model, as was the down-regulation of such genes (CYP7A1, HMGCR, GCK and PNPLA3) and the up-regulation of expression of hepatic genes related to liver cancer (E2F1, OPCML, FZD7, IGFBP1 and LEF1).
|
26442469 |
2015 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3, but not the APOC3 rs2854116 SNP, was associated with fatty liver but not with triglyceride levels.
|
22105854 |
2012 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We showed for the first time, to our knowledge, that carriers of the PNPLA3 148M allele with either fatty liver plus obesity or obesity alone have lower fasting circulating retinol concentrations.
|
26136587 |
2015 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In patients without, but not in those with NASH, significant fibrosis was associated with steatosis grade and the PNPLA3 I148M variant.
|
30708111 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, PNPLA3 rs2294918 rs2294918" genes_norm="80339">E434K decreased PNPLA3 expression, lessening the effect of the I148M variant on the predisposition to steatosis and liver damage.
|
26605757 |
2016 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SNP rs738409 in the adiponutrin gene (PNPLA3) is a well described factor for steatosis.
|
23870067 |
2014 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, one-third of HIV/HCV-coinfected patients are affected by HS with PI-based ART and PNPLA3 impacting on HS prevalence.
|
31067123 |
2019 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Interleukin-28B (IL28B) and patatin-like phospholipase domain containing 3 (PNPLA3) gene polymorphisms are associated with hepatitis C virus (HCV) clearance and fatty liver, respectively.
|
25639146 |
2015 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The G-allele of PNPLA3 rs738409 was associated with NAFLD (odds ratio [OR] 1.55, 95% confidence interval 1.13-2.11, P = 0.006) and moderate-to-severe steatosis (OR 3.77, 95% confidence interval 1.78-7.98, P = 0.001) adjusted for age, sex, and BMI standard deviation score.
|
25522307 |
2015 |
Steatohepatitis
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The presence of the TM6SF2 c.499A allele in the donor (p=0.014), the PNPLA3 c.444G allele in the donor (p<0.001), posttransplant BMI (p<0.001) and serum triglycerides (p=0.047) independently predicted increased liver fat content on multivariable analysis whereas noncirrhotic liver disease as an indication for liver transplantation was associated with lower risk of steatosis (p=0.003).
|
31356578 |
2020 |
Steatohepatitis
|
0.500 |
Biomarker
|
disease |
BEFREE |
Steatohepatitis was associated with all-cause mortality [Hazard ratio (HR) 3.1, 95%CI: 1.3-7.3, P = 0.006] and HCC (HR 2.8, 95%CI: 0.9-9.2, P = 0.078), but no significant association was observed for PNPLA3.
|
25284145 |
2015 |